Last reviewed · How we verify
Acacia Pharma Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
5 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| APD421 | APD421 | phase 3 | NK1 receptor antagonist | NK1 receptor (neurokinin-1 receptor) | Oncology / Anesthesia | |
| APD421- Amisulpride for IV injection | APD421- Amisulpride for IV injection | phase 3 | Dopamine antagonist / Antiemetic | Dopamine D2 receptor, Dopamine D3 receptor | Gastroenterology / Perioperative Medicine |
Therapeutic area mix
- Anesthesiology · 2
- Gastroenterology / Perioperative Medicine · 1
- Neurology · 1
- Oncology / Anesthesia · 1
- Oncology / Gastroenterology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Organon and Co · 2 shared drug classes
- University of North Carolina, Chapel Hill · 2 shared drug classes
- CCTU · 2 shared drug classes
- H. Lundbeck A/S · 2 shared drug classes
- Otsuka Pharmaceutical Co., Ltd. · 2 shared drug classes
- Shanghai Mental Health Center · 2 shared drug classes
- AstraZeneca · 2 shared drug classes
- American University of Beirut Medical Center · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Acacia Pharma Ltd:
- Acacia Pharma Ltd pipeline updates — RSS
- Acacia Pharma Ltd pipeline updates — Atom
- Acacia Pharma Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Acacia Pharma Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/acacia-pharma-ltd. Accessed 2026-06-10.